论文部分内容阅读
目的观察尼莫地平治疗急性脑出血的临床疗效和安全性。方法对60例起病在48h内经头颅CT证实的急性脑出血患者,随机分为治疗组和对照组,治疗组在常规治疗的基础上给予尼莫地平注射液静脉滴注,连用21d。比较两组治疗前后,颅内血肿体积,患者神经功能缺损程度评分,血肿周围水肿带面积的改变及临床疗效和继续出血、再出血及血压变化情况。结果治疗组总有效率为90%与对照组比较具有明显统计学差异(P<0.05),治疗组血肿周围水肿带面积明显缩小(P<0.05),神经功能缺损评分明显改善(P<0.01),血肿体积改变不明显,没有出现再出血,血压明显降低及颅内压明显增高的的不良反应。结论在脑出血的急性期给予尼莫地平治疗,可明显改善病情,安全有效,无明显不良反应。
Objective To observe the clinical efficacy and safety of nimodipine in the treatment of acute cerebral hemorrhage. Methods Sixty patients with acute cerebral hemorrhage confirmed by skull CT within 48 hours were randomly divided into treatment group and control group. The treatment group received nimodipine injection intravenously on the basis of routine treatment for 21 days. Before and after treatment, the volume of intracranial hematoma, the score of neurological deficit, the area of edema around hematoma, the clinical curative effect and the continuous hemorrhage, rebleeding and blood pressure were compared. Results The total effective rate was 90% in the treatment group compared with the control group (P <0.05), and the edema area around the hematoma in the treatment group was significantly reduced (P <0.05) and the neurological deficit score was significantly improved (P <0.01) , Hematoma volume change is not obvious, there is no rebleeding, blood pressure was significantly lower and intracranial pressure was significantly higher adverse reactions. Conclusion Nimodipine is given in the acute phase of intracerebral hemorrhage, which can significantly improve the condition, be safe and effective, and have no obvious adverse reactions.